Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer.
David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Articles by David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
4
The Intersection of Technology and Psycho-Oncology Care
5